Seldom do I venture outside the subject matter of constitutionalism, ideology and/or politics, but when I do it is either something personal, remarkable or both. The unique and innovative research and development taking place at Galectin Therapeutics™ is just such a subject. Should the scientists of this corporation succeed in bringing their product to market, the lives of millions of people in the United States – and potentially tens, if not hundreds of millions of people around the world – could be saved.
This issue is important to me because I have a personal experience with the evils of cancer and the fibrotic diseases. In 2000, my best friend from high school (a brother from the moment we met until the day he died) was taken from me, from his family, by the ravages of these diseases. He was diagnosed and taken in less than 30 days. The emotional toll on all his survivors was all encompassing and intense. It is with this personal understanding of the issue that the discovery of what Galectin Therapeutics is doing captivated my attention.
What would you say if I told you that a company – a gifted group of scientists – has developed a therapy that will save the lives of well over 15 million Americans suffering from diseases that currently have no cure, and that today can’t be detected until it is too late?
What would you say if I told you that the Food & Drug Administration is so impressed with the data surrounding this new drug therapy that they have awarded “Fast Track” status to this drug, and that, according to Morgan Brennan of CNBC Business News, there has never – never – been a Fast Tracked drug that has failed to come to market?
And what would you say if I told you that not only will this drug be extremely affordable when it comes to market, but that you – you – could be a part of this history-making endeavor?
Well, it is all true…and none-to-soon for the many people who suffer from fibrosis of the liver, kidneys and lungs, and some forms of cancer, thanks to groundbreaking work being done by the scientists at Galectin Therapeutics.